Introduction
The slowly-activating delayed rectifier I Ks , a major repolarizing K + current in he art, is formed by co-assembly of the α -subunit KCNQ1 and the β -subunit KCNE1 (Barhanin et al., 1996; Sanguinetti et al., 1996) . Mutations in either of the subunits cause congenital long QT syndrome. In addition, KCNQ1 and I Ks channels are targets for multiple drugs with antiarrhythmic or proarrhythmic actions. These include nonselective drugs used to treat arrhythmias, such as quinidine (Balser et al., 1991) amiodarone (Kamiya et al., 2001 ) azimilide (Busch et al., 1997) and clofilium (Yang et al., 1997) as well as drugs designed as specific I Ks blockers such as L-7 (Seebohm et al., 2003b) , HMR-1556 (Gogelein et al., 2000) and chromanol 293B (Bosch et al., 1998) . In addition, drugs not used in antiarrhythmic therapy have been reported to activate cardiac I Ks , such as stilbenes/fenamates (Abitbol et al., 1999) and R-L3 (Seebohm et al., 2003c) .
The S6 domain helix, lining the pore of many voltage-gated ion channels, has been identified as a key site for high-affinity drug binding and block in the ion channels. This includes the S6 region of domains II and IV in Na + channels (e.g., local anesthetics and antiarrhythmics) and L-type Ca 2+ channels (dihydropyridines). Among K + channels, the S6 segment has been identified as a ke y region determining drug block of HERG (KCNH2) and Kv1.5 (KCNA5) channels. In KCNH2, the S6 aromatic residues I647, Y652, and F656 have previously been identified as binding sites for I Kr /HERG blockers (Ishii et al., 2001; Mitcheson et al., 2000; Perry et al., 2004) . Mutation of these sites to alanine renders the HERG channel resistant to specific I Kr inhibitors (such as dofetilide and MK-499) and the non-specific blocker quinidine. Quinidine interacts with S6 residues in KCNA5 to inhibit the expressed current (Yeola et al., 1996; Snyders and Yeola, 1995) . Previous studies (Seebohm et al., 2003a; Seebohm et al., 2003b; Seebohm et al., 2003c) have similarly identified S6 residues required for benzodiazepine I Ks agonist (R-L3) or antagonist (L-7) binding. In these studies, a common feature of r esidues identified for d rug block is that they are predicted to interact with the binding drug by facing the permeating pore.
In the present study, we initially used alanine/cysteine scanning mutagenesis of an extensive region of S6 segment and the proximal C-terminus to identify residues important for drug block. However, homology modeling suggested that key residues identified in this way
were not oriented toward the channel pore. This suggests that alternative mechanism could be involved in drug binding and/or block. Accordingly, further studies were conducted that implicate drug binding within a side pocket which is formed by several S6 and S4-S5 linker residues, previously identified as likely interacters with the C-terminal end of S6 segment ( Boulet et al. 2007; Choveau et al. 2011; Labro et al. 2011) adjacent to the channel pore as a mechanism of allosteric ion channel block.
Materials and Methods
Site-Directed Mutagenesis. A total of 48 amino acid residues in the S6 segment (30 residues, V324 to L353), S4-S5 linker (3 residues), and the proximal C-terminus (15 residues, K354 to I368) of KCNQ1 channel were substituted individually with alanine by recombinant PCR mutagenesis; five wild-type (WT) alanines (A329, A336, A341, A345 and A352) were individually substituted with cysteines. For each mutation, four primers were used: two were mutagenic primers, and two were flanking primers. The mutagenic primers contained the desired point mutation at their center, and were complementary to each other. The flanking primers were complementary to target sequences 5' and 3' of the desired mutation. They were chosen to abut convenient restriction sites to allow those sites to be used for reinsertion into the target sequence.
The target sequence was denatured and the mutagenic primers were annealed and extended using Taq polymerase. The two extension products carrying the point mutations close to their 5' ends were then allowed to anneal and were then extended, creating a DNA duplex with the mutation roughly at the center. The mutagenic primers were then removed using a Q IAquick PCR Purification Kit (QIAGEN Inc. Chatsworth, CA) following the manufacturer's instructions. The two flanking primers were then used in a s tandard PCR reaction using the mutated DNA as template. The resulting mutated PCR fragment was then inserted into the target sequence via the restriction sites within the flanking primers. Standard PCR conditions used to accomplish these reactions included 10-100ng of template DNA, 40 pMol each primer, 10 mmol/L Tris (pH 9.0, room temperature), 1.5 mmol/L MgCl 2 , 50 mM KCl, 0.1 % Triton X-100, 0.2 mmol/L each dATP, dCTP, dGTP, dTTP and 5 units of Taq DNA polymerase. The temperature profiles used typically were: 95 °C for 5 min at which point the polymerase was added. This was followed by Whole-Cell Voltage Clamp. The voltage-clamp studies were performed using the same methods as previously reported (Kanki et al., 2004; Yang et al., 2003; Abraham et al., 2009; Yang et al., 2009 (Smith et al., 2007) . The open-state model is based upon the crystal structure of the mammalian Kv1.2 potassium channel (Long et al., 2005) . T his structure provides a template for not only the pore domain (S5-P-S6) of the channel but also the sensor domain helices (S1-S4), and key to this study, the S4-S5 linker. Side chain identities were missing for S1 and S3 helices in the template crystal structure, and no coordinates are available for the loops in the sensor. One of these rotamers was manually placed into the pocket located between subunit A and B of KCNQ1 to provide the docking software with a rough guideline for where to initially place quinidine. Each of the 470 quinidine rotamers was then automatically placed and optimized by the RosettaLigand Monte-Carlo refinement routines in Rosetta 3.0 with full flexibility for the ligand and protein sidechains. E xtra rotamers (-ex1, -ex1aro, -ex2) were used for both buried and surface protein residues. The improve_orientation option was also enabled to place and test 1000 random orientations of the ligand in the pocket in order to improve its positioning before the Monte Carlo search began. The abbrev2 protocol was used with ligand minimization, harmonic torsions and protein backbone atom minimization, allowing the Cα atoms to move up to 0.3Å from initial positions. These calculations resulted in 10,000 docked complexes, which were then ranked by the RosettaLigand interface score for further analysis. 
Results
Sites of Drug Block. In a first set of experiments, we assessed the effects of quinidine at a concentration (100 µM) that inhibits wild type KCNQ1 current by ≥ 90% ( Figure 1A ). Figures 1B-D show results with the three mutants most resistant to drug block among the 45 residues tested: F351A, L353A, and K358A. Notably, all three are located in the proximal C-terminus of the protein, and not in the intracellular region of S6.
In these experiments, we noted that some mutations display dramatic gating changes, including F351A which shows an "I Ks -like" behavior ( Figure 1B ), as previously reported (Boulet et al., 2007; Ma et al., 2011) . To address the possibility that mutagenesis-induced changes in F351A channel kinetics influence drug block, we examined current-voltage (I-V) relationships prior to and after quinidine. As shown in Figure 2A /B, current amplitudes for F351A with and without quinidine were unaffected, confirming that F351A is insensitive to quinidine block.
Compared to the wild-type KCNQ1 channel ( Figure 2C ), however, the F351A channel activates very slowly with a large positive voltage shift by ~+40 mV. Further, while we have previously reported that wild-type KCNQ1 channels are less sensitive to quinidine than I Ks (Yang et al., 2003) , the "I Ks -like" F351A channels are insensitive to quinidine ( Figure 2D ).
We also assessed concentration-response relations for quinidine block in two aromatic residue mutations (F332A and F 335A) in the S6 segment. A s shown in F igure 2E-F, while quinidine blocked the wild-type KCNQ1 channel with an IC 50 value of 19.4 ±1.7 µM, the F332A and F335A channels were much less sensitive, with IC 50 values of ~120 µM and >300 µM, respectively. Figure 3A summarizes the data for all 45 mutants in the distal S6 and proximal Cterminal regions. Aromatic residues within the pore region displayed variable sensitivity to drug block, greatest with F332 and F335, and near WT sensitivity for F339 and F340. F igure 3B
shows that this effect is not quinidine-specific, and was also seen with a high concentration of clofilium (30 µM).
Since both quinidine and clofilium are non-selective blockers, we also tested the effects predicted that the residues (F351, L353 and K358) displaying the greatest insensitivity to drug block were pointing away from the channel and/or making contact with the S4-S5 linker ( Figure   5 ). Further, the model predicted that three S4-S5 residues (L250, L251 and V254) would form a hydrophobic "pocket" into which the phenyl ring of res idue F351 fits. T his model, therefore,
suggests that this pocket may in f act be a s ite at w hich quinidine interacts with the channel protein.
Drug Block at Key S4-S5 Linker Residues. To further examine this prediction, we evaluated the drug sensitivity of the L251A and V254A mutants in the S4-S5 linker. Figure 6 shows that the L251A and V254A mutants both displayed moderately reduced current amplitude at baseline with or without KCNE1 coexpression, with slowed activation of I KCNQ1 with L251A.
The most striking finding, however, was that these mutant channels displayed highly reduced sensitivity to drug block. For example, while 100 µM quinidine reduced WT currents by 94±5% (I KCNQ1 ) and 96±3% (I Ks ), the corresponding reductions of the currents for L251A were 32±6%
and 34±4% and 39±7% and 40±5% for V254A. In our study, the mutant L250A did not generate any current for drug test, in good agreement with another work .
There are three LQT1 mutations (L250H, V254L and V254M) located in the KCNQ1 S4-S5 linker (Napolitano et al., 2005; Zareba et a l., 2003; Kapa et al., 2009) . We generated these mutants to determine their biophysical properties and block by quinidine. L250H and V254M expressed very small (or absent) currents, so evaluation of drug block was not possible. The V254L mutation also generated a reduced current: even with KCNE1 coexpression, the mutant I Ks amplitude was 1846±175 pA vs. 3683±254 (WT-I Ks ) pA at +60 mV (p<0.01, n=5 each). We found that the mutation was markedly resistant to drug block: 100 µM quinidine reduced V254L-I Ks by 36±3% vs 97±2% for (WT-I Ks ) reduction at +60 mV.
Quinidine Docking in the KCNQ1 Channel. To explore possible binding modes and interaction surfaces, a model of quinidine was
docked into the open-state cavity described above using RosettaLigand automated docking routines in Rosetta 3.0. Docking calculations resulted in 10,000 docked complexes, which were then ranked by the RosettaLigand interface score. Docking small molecules into a comparative model is intrinsically difficult, given that the binding pocket model is potentially inaccurate at atomic detail. Therefore, we do not expect to necessarily recover the exact binding pose of quinidine. However, we do expect to obtain a qualitative view of its general binding region and contacts it makes with neighboring residues. Thus, we analyzed the top 10 scoring models for quinidine-protein contacts. These contacts are summarized in Table 1 , and the complex with the best interface score is shown in F igure 8, hig hlighting the locations of these contacts. Close contacts between quinidine and F351/L251/V254 are observed in every one of t hese top 10 scoring models. This correlates extremely well with the experimental evidence that these three residues are involved with quinidine block, and strengthens our hypothesis that the mechanism is an allosteric modulation induced by quinidine binding at the site we have identified.
Discussion
In this study, we used a combination of alanine/cysteine mutagenesis, patch clamp, and homology modeling to identify a novel allosteric mechanism for drug block of the human cardiac K + channel KCNQ1. We have found a previously unrecognized role of the S4-S5 linker and the proximal C-terminus in modulating drug block of the KCNQ1 channel. In an open-state channel model based on the Kv1.2 structure, we have strong evidence that block does not occur via binding to a s ite within the channel pore through where K + permeates. R ather, the structural model predicts that the key residue, F351, is oriented into a pocket also lined by S4-S5 residues, and that mutagenesis at these pocket sites also restricts quinidine block. Taken together, the findings support a model in which quinidine binds to residues within this pocket and thus blocks this channel by an allosteric mechanism.
In the studies of drug block, inhibition of ion current through drug binding to sites within the ion conducting pathway (the inner pore of t he channel, especially in S6 segment) has been implicated as a common mechanism for ion channel block. The block becomes more prominent when the channel is activated to open, or the open channel block. Previous studies (Chen et al., 2002; Mitcheson et al., 2000; Perry et al., 2004) with HERG implicated two aromatic residues, I647 and Y652 oriented toward the ion conducting pore, as key sites affecting this type of block.
In this study, interestingly, mutagenizing along S6 and into the proximal C-terminus of this channel failed to identify these residues as key binding sites, but rather identified residues more distal in S6 and within the C-terminus as key ones. Other studies (Seebohm et al., 2003b; Thomas et al., 2003) have reported that specific I Ks blockers (e.g., L-7 and HMR-1556) bind to multiple potential interacting sites in the pore and S 6 areas of KCNQ1 to inhibit the KCNQ1 current.
And studies have shown that HERG or KCNQ1 channel activators may enhance currents through interaction with residues in the S4-S5 linker of the channel (Perry et al., 2007; Perry et al., 2009) .
In this study, we have also observed that several KCNQ1 mutations (L251A, V254A and V254L) in the S4-S5 linker display remarkable resistance to block by a hig h concentration of quinidine.
Homology structural modeling and docking of a channel active drug have been broadly used to understand molecular basis of the drug-channel interaction. The HERG channel studies used homology modeling to the crystallized K + channel KcsA structure to support a model of drug-channel interaction suggested by the electrophysiologic data on alanine-substituted mutants.
Then an obvious question is whether our data on KCNQ1 drug block can similarly be supported.
To further learn how the residue F351 might limit drug block, we have used crystallized K suggests that the aromatic residue points toward the channel pore (data not shown). In addition, F340 appears very close to F351 in the adjacent KCNQ1 monomer, raising the possibility that the blocker interacts with dual sites on adjacent subunits; however this would not explain our finding that F340A displayed drug sensitivity that was not significantly different from WT channel. Our docking study correlates well with these data, as none of the best scoring proteinligand complex models predict contacts between quinidine and F340, as the side-chain for this residue is on th e wrong side of th e S6 helix in the adjacent subunit, and therefore facing away from the proposed binding site.
Based on the Kv1.2 structure, our homology modeling of KCNQ1 unexpectedly suggested that residue F351 faces away from the permeating pore. This finding argues against pore block as the mechanism for drug inhibition of KCNQ1 current. In the open-state channel model of the Kv1.2 structure, F351 lines a side "pocket" that is also associated with residue L251
and V254 in the S4-S5 linker. T he model allows drug access to this pocket, and alanine substitutions at both sites yielded K + currents that were resistant to quinidine block (↓34±4% for L251A and ↓ 40±5% for V2 54A; Figure 6 ). This further supports the concept that the S4-S5
linker and proximal C-terminus play an im portant role in m odulation of drug block of the channel. Other studies with two HERG channel activators have also indicated importance of interaction between S4-S5 linker and S6 segment, as well as drug binding to these regions (Perry et al., 2007; Perry and Sanguinetti, 2008; Perry et al., 2009 ).
Previous studies have suggested that t he S4-S5 linker interacts with the C-terminal portion of S6 segment, and this interaction provides a mechanism whereby depolarization allows movement of the S4 voltage sensor to be transduced into channel opening Choveau et al., 2011) . Mutations (L353A, V254A and V254L) tested here lead to disruption of this interaction, and peptides modeled on the S4-S5 linker similarly inhibit KCNQ1 current (Boulet et al., 2007; Labro et al., 2011) . T hus, the reduced quinidine block observed in the L353A, V254A and V254L mutants may also reflect disruption of the interaction between the S4-S5 linker and the S6 domain, a similar mechanism could underlie the effect we see with the F351A S6 mutant. It is well known that point mutations in the S6 segment and pore regions of K + channels may alter channel gating, and such changes in turn can modulate drug block; thus it may be difficult to separate the effects of drug sensitivity and g ating that the mutations may confer. Previous structure-function studies of high-affinity drug binding in HERG channels have provided evidence that intact C-type inactivation is important for drug binding, because some mutations with disrupted inactivation markedly attenuated sensitivity to specific I Kr blockers.
This effect results most likely from allosteric changes in the drug binding site in HERG channels.
The KCNQ1 channel alone shows some inactivation which can be removed by the β subunit KCNE1. In fact, two S6 mutants, F339A and F340A, did display ultra-fast inactivation (data not shown), but did not affect block by quinidine and clofilium in this study. In addition, slowed activation for F351A did not also influence the sensitivity to the channel to the blockers. Other researchers have also found that gating alterations in the KCNQ1 channel mutations had no or little interference in determining the effects of drugs on the channel (Seebohm et al., 2003a-c) .
These data are in good agreement with a report showing that mutations altering KCNQ1
inactivation showed no changes in sensitivity to a potent I Ks blocker L-7 (Seebohm et al., 2003b) .
Taken together, our data in the present study strongly support a m odel in w hich open state block of t his channel occurs not via binding to a site in the pore but rather by a novel allosteric mechanism, drug access to a side pocket generated in the open-state channel configuration and lined by S6 and S4-S5 residues. T hese findings may form the basis for development of new classes of channel blockers. and clofilium (30 µM). Drug block was assessed using a single 1-sec pulse protocol to +60 mV from -80 mV. Steady-state block was measured at the end of activating current (n=4-8 each). T264 and I268 are both from the neighboring subunit (green ribbon) and the others are from the same subunit as F351 (yellow ribbon). S ide chains for K358 and L353 sites, which are also highly resistant to drug block, are shown in yellow. Representative traces prior to and after quinidine are presented in individual panels. Drug block was assessed using a single pulse protocol to +60 mV from -80 mV for 1 sec (for I KCNQ1 ) or 5 sec (for I Ks ). 4Å of quinidine atoms in more than 50% of the 10 be st-scoring complexes. Q uinidine was docked in the cavity between KCNQ1 subunits A and B (The red volume located between the cyan and green subunits in Figure 7) . A "10" in column 4 means that the residue identified in columns 1-3 was in contact with quinidine in every one of the 10 best-scoring complexes. Note that contacts between quinidine and F351/L251/V254 (bold) are observed in every one these models. Th is correlates exactly with our experimental evidence that these three residues are involved with quinidine block, and strengthens our hypothesis that the mechanism is an allosteric modulation induced by quinidine binding at this site. 
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